GB8602264D0 - Administering medicaments to patients - Google Patents

Administering medicaments to patients

Info

Publication number
GB8602264D0
GB8602264D0 GB8602264A GB8602264A GB8602264D0 GB 8602264 D0 GB8602264 D0 GB 8602264D0 GB 8602264 A GB8602264 A GB 8602264A GB 8602264 A GB8602264 A GB 8602264A GB 8602264 D0 GB8602264 D0 GB 8602264D0
Authority
GB
United Kingdom
Prior art keywords
patients
administering medicaments
medicaments
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8602264A
Other versions
GB2169265A (en
GB2169265B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838314307A external-priority patent/GB8314307D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB8602264A priority Critical patent/GB2169265B/en
Publication of GB8602264D0 publication Critical patent/GB8602264D0/en
Publication of GB2169265A publication Critical patent/GB2169265A/en
Application granted granted Critical
Publication of GB2169265B publication Critical patent/GB2169265B/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0003Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • A61M15/0035Piercing means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/60General characteristics of the apparatus with identification means
    • A61M2205/6063Optical identification systems
    • A61M2205/6081Colour codes
GB8602264A 1982-10-08 1986-01-30 Pack for medicament Expired GB2169265B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB8602264A GB2169265B (en) 1982-10-08 1986-01-30 Pack for medicament

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8228887 1982-10-08
GB838314307A GB8314307D0 (en) 1983-05-24 1983-05-24 Medical administration devices
GB8602264A GB2169265B (en) 1982-10-08 1986-01-30 Pack for medicament

Publications (3)

Publication Number Publication Date
GB8602264D0 true GB8602264D0 (en) 1986-03-05
GB2169265A GB2169265A (en) 1986-07-09
GB2169265B GB2169265B (en) 1987-08-12

Family

ID=27261782

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8602264A Expired GB2169265B (en) 1982-10-08 1986-01-30 Pack for medicament

Country Status (1)

Country Link
GB (1) GB2169265B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280967B6 (en) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalation device
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9012870D0 (en) * 1990-06-08 1990-08-01 Glaxo Group Ltd Device
GB9016789D0 (en) * 1990-07-31 1990-09-12 Lilly Industries Ltd Medicament administering devices
US5042472A (en) * 1990-10-15 1991-08-27 Merck & Co., Inc. Powder inhaler device
US5337740A (en) * 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
DE19647947A1 (en) * 1996-11-20 1998-05-28 Pfeiffer Erich Gmbh & Co Kg Discharge device for media
SE9900188D0 (en) * 1999-01-22 1999-01-22 Astra Ab Dispensing device
US6810872B1 (en) 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
AR032361A1 (en) 2000-08-05 2003-11-05 Glaxo Group Ltd DERIVATIVES OF ANDROSTAN AND SALTS AND SOLVATOS OF THE SAME, ITS USE FOR THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS, AND USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
EP1416990A1 (en) * 2001-08-09 2004-05-12 Glaxo Group Limited Inhalation device with a pharmaceutical composition
BRPI0212455B8 (en) 2001-09-14 2021-05-25 Glaxo Group Ltd compound derived from phenethanolamine for the treatment of respiratory diseases, pharmaceutical formulation, combination, and use thereof
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
DE60318193T2 (en) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford PHENETHANOLAMINDERIVATE
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
US7442839B2 (en) 2002-10-28 2008-10-28 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20050250A1 (en) 2003-07-17 2005-04-08 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
ATE494285T1 (en) 2003-10-14 2011-01-15 Glaxo Group Ltd MUSCARINE ACETYLCHOLINE RECEPTOR ANTAGONISTS
AP2006003575A0 (en) 2003-10-17 2006-04-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists.
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
BRPI0509382A (en) 2004-04-02 2007-09-18 Glaxo Group Ltd process for the preparation of a compound monohydrochloride salt, crystalline monohydrochloride, process for obtaining crystalline monohydrochloride, method for the prophylaxis or treatment of a clinical condition in a mammal, use of crystalline monohydrochloride, pharmaceutical formulation, and, combination
AR050902A1 (en) 2004-04-27 2006-12-06 Glaxo Group Ltd QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION
EP1747219A4 (en) 2004-05-13 2010-05-26 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists field of the invention
EP1848444B1 (en) 2005-02-10 2016-11-09 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
PE20100741A1 (en) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
PE20061351A1 (en) 2005-03-25 2007-01-14 Glaxo Group Ltd 8H-PYRID [2,3-d] PYRIMIDIN-7-ONA 2,4,8-TRISUSTITUTED COMPOUNDS AS CSBP / RK / p38 KINASE INHIBITORS
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
DK2400950T3 (en) 2009-02-26 2019-07-29 Glaxo Group Ltd PHARMACEUTICAL FORMULA comprising 4 - {(1 R) -2 - [(6- {2 - [(2,6-DICHLORBENZYL) OXY] ETHOXY} HEXYL) AMINO] -1-HYDROXYETHYL} -2- (HYDROXYMETHYL) PHENOL
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2611422B1 (en) 2010-08-31 2018-10-31 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
ES2546422T5 (en) 2010-08-31 2023-01-20 Glaxosmithkline Ip Dev Ltd Dry powder inhalation medicinal products having moisture control properties and methods of administration thereof
WO2012064286A1 (en) 2010-11-11 2012-05-18 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
JP6182594B2 (en) 2012-04-27 2017-08-16 グラクソ グループ リミテッドGlaxo Group Limited New compounds
EP2925328A1 (en) 2012-11-28 2015-10-07 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
AR103891A1 (en) 2015-03-11 2017-06-14 Glaxosmithkline Ip Dev Ltd PROTEINAS OF UNION TO TSLP, ISOLATED NUCLEIC ACID THAT CODIFIES IT, VECTOR AND HOSPEDADORA CELL THAT UNDERSTAND IT, METHOD TO PRODUCE THE PROTEIN SAID, ITS USE TO MANUFACTURE A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION AND COMPLAINT KIT
CN108112251B (en) 2015-06-15 2021-03-05 葛兰素史克知识产权发展有限公司 NRF2 modulators
EP3307729B1 (en) 2015-06-15 2020-09-02 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
KR20180017038A (en) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 NRF2 modulator
UY36851A (en) 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS
EP3371167A1 (en) 2015-10-06 2018-09-12 GlaxoSmithKline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as nrf2 regulators
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
JP2019532054A (en) 2016-09-20 2019-11-07 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
JP7106528B2 (en) 2016-09-20 2022-07-26 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド TRPV4 antagonist
TW201825458A (en) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 TRPV 4 antagonists
WO2018104766A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators
JP2020500918A (en) 2016-12-12 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited N-arylpyrazoles as NRF2 regulators
JP2020500919A (en) 2016-12-12 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Pyrrole 3-carboxylate as NRF2 regulator
JP2020502136A (en) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Bisarylamides as NRF2 regulators
EP3555078B1 (en) 2016-12-14 2024-03-27 GlaxoSmithKline Intellectual Property Development Limited Bisaryl heterocycles as nrf2 activators
JP2020502129A (en) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 3-oxo-1,4-diazepinyl compounds as NRF2 activators
BR112019012300A2 (en) 2016-12-15 2019-11-12 Glaxosmithkline Ip Dev Ltd nrf2 activators
EP3555082B1 (en) 2016-12-15 2022-01-26 GlaxoSmithKline Intellectual Property Development Limited Ether linked triazoles as nrf2 regulators
AU2018257778B2 (en) 2017-04-24 2022-02-17 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
JP2021505636A (en) 2017-12-11 2021-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited NRF2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ failure syndrome
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
GB201720989D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111868063B (en) 2018-01-17 2023-08-01 葛兰素史克知识产权开发有限公司 PI4KIII beta inhibitors
EP3796906A1 (en) 2018-05-23 2021-03-31 GlaxoSmithKline Intellectual Property Management Limited Indanes as nrf2 activators
CA3106556A1 (en) 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
WO2020055858A1 (en) 2018-09-10 2020-03-19 Cocrystal Pharma, Inc. Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
BR112021007275A2 (en) 2018-10-17 2021-07-20 Cocrystal Pharma, Inc. combinations of influenza virus replication inhibitors
CN113164612A (en) 2018-11-13 2021-07-23 共晶制药公司 Formulations of influenza therapeutics
WO2020112716A1 (en) 2018-11-26 2020-06-04 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
GB201908536D0 (en) 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
US20230151034A1 (en) 2020-03-17 2023-05-18 Cocrystal Pharma, Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
IL297069A (en) 2020-04-10 2022-12-01 Cocrystal Pharma Inc Inhibitors of norovirus and coronavirus replication
EP4138884A1 (en) 2020-04-20 2023-03-01 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
IL310394A (en) 2021-08-03 2024-03-01 Cocrystal Pharma Inc Inhibitors for coronaviruses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB516834A (en) * 1937-12-23 1940-01-12 Charles Alexandre Nicolle Improvements in or relating to packaging
US3038282A (en) * 1960-07-05 1962-06-12 American Cyanamid Co Capsules of soft plastic containing granules
CH385718A (en) * 1961-11-04 1964-12-15 Bodet Jean Method and device for packaging solid articles of small volume, and assembly obtained by this method
CH411232A (en) * 1963-11-12 1966-04-15 Ciba Geigy Drug packaging
GB1387954A (en) * 1973-05-08 1975-03-19 Miles Lab Insufflator
CH581992A5 (en) * 1975-08-15 1976-11-30 Laib Jakob C
US4342395A (en) * 1981-02-02 1982-08-03 Brown James B Liquid dispensing unit and method of manufacture thereof

Also Published As

Publication number Publication date
GB2169265A (en) 1986-07-09
GB2169265B (en) 1987-08-12

Similar Documents

Publication Publication Date Title
GB8326878D0 (en) Administering medicaments to patients
GB8602264D0 (en) Administering medicaments to patients
GB2178965B (en) Devices for administering medicaments to patients
ZA82124B (en) Bandage for administering beneficial drug
GB8327748D0 (en) Medicinal preparation
DE3166709D1 (en) Inhalation device for administering medicaments
GB8304809D0 (en) Connecting respirator/anesthesia machine to patient
GB8813175D0 (en) Medicinal/therapeutic pack
GB8418367D0 (en) Medicinal preparation
ZA837318B (en) Device for administering medicaments to patients
GB8403257D0 (en) Medicinal preparation
GB8525067D0 (en) Administering medicaments to patients
GB8519141D0 (en) Administering medicaments to patients
ZA833721B (en) Administering fluid to patients
GB8316632D0 (en) Administering medicaments
GB8303270D0 (en) Administering fluid to patients
ZA812634B (en) Breath actuated devices for administering powered medicaments
GB8414737D0 (en) Dose administering device

Legal Events

Date Code Title Description
727B Case decided by the comptroller ** specification amended (sect. 27/1977)
711A Proceeding under section 117(1) patents act 1977
PE20 Patent expired after termination of 20 years

Effective date: 20031006